Related Experiment Video

Updated: Mar 31, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K

Targeting Signaling Transduction Pathways in Bladder Cancer

Phillip H Abbosh1, David J McConkey2,3, Elizabeth R Plimack4

  • 1Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA. philip.abbosh@fccc.edu.

Current Oncology Reports
|October 17, 2015
PubMed

Insights

Targeted therapies show promise for urothelial carcinoma (UC) treatment by inhibiting specific signal transduction pathways. These therapies are being explored for both localized and metastatic UC, offering a new approach beyond traditional chemotherapy.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Systemic therapy for urothelial carcinoma (UC) primarily uses cytotoxic chemotherapy.
  • Recent next-generation sequencing (NGS) studies reveal genetic derangements in signaling pathways in UC.
  • These genetic alterations, including point mutations and copy number alterations (CNA), are present across all disease stages.

Purpose of the Study:

  • To review the rationale for targeted therapies in urothelial carcinoma treatment.
  • To summarize the progress in studying signal transduction pathway inhibition for UC.
  • To explore targeted therapies as a next step in managing localized and metastatic UC.

Main Methods:

  • Review of recent clinical trials exploring targeted therapies.
  • Analysis of next-generation sequencing (NGS) data identifying genetic alterations in UC.
  • Examination of the role of signal transduction pathways in UC development and progression.

Main Results:

  • Targeted therapies inhibiting specific signal transduction pathways are under investigation.
  • Genetic derangements in signaling pathways are common in urothelial carcinoma.
  • Targeted therapies offer potential for both localized and metastatic urothelial carcinoma.

Conclusions:

  • Targeted therapies represent a promising evolution in urothelial carcinoma management.
  • Inhibition of aberrant signal transduction pathways provides a targeted treatment strategy.
  • Further research into targeted therapies is crucial for advancing UC treatment options.
Keywords:
BevacizumabBladder cancerCetuximabChemotherapyCopy number abnormalityDovitinibEGFRERBB2ERBB3ErlotinibEverolimusFGFR3MutationPIK3CAPTENPazopanibSunitinibmTOR

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
8.6K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
11.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K